

**Gynecologic Cancer InterGroup
Cervix Cancer Research Network**



Cervix Carcinoma Case: Metastatic

Dr Mariza Tunmer
Radiation Oncologist
Johannesburg

Cervix Cancer Education Symposium, January 2019, South Africa

Gynecologic Cancer InterGroup Cervix Cancer Research Network



Cervix Carcinoma: Metastatic

Ms TL

32yr

17 March 2016

Presented to local hospital casualty with nausea & vomiting, abd pain;

Cervix Cancer Education Symposium, January 2019, South Africa

Gynecologic Cancer InterGroup Cervix Cancer Research Network



P1G1 2 year old child; Single mother.

PMhx: Nil of note; RVD negative

PShx: C/S; Ankle injury; Breast augmentation;

Social: Smoker, 6 pack years

Occupation: Administrative Manager

Fam hx: Maternal Grandmother: Lymphoma at 71 years of age

Gynecologic Cancer InterGroup Cervix Cancer Research Network



In casualty: seen by a Surgeon

Dx with a peptic ulcer – PPI, Stilpayne;

Abd-pelvic ultrasound 17 March 2016

Cervix mass – 6.4 x 5.6cm

Endometrial stripe normal and no fluid in the uterus; ovaries normal;

Liver normal; Kidneys normal; Bladder normal;

No comment on LNs

D/C from casualty – Referral to Gynae

Gynecologic Cancer InterGroup Cervix Cancer Research Network



Gynae: Pt assessed as ca cx Stage IIIB

PAP 24 Mar 2016 Suspicious for squamous carcinoma

Biopsy 1 April 2016 Moderately differentiated keratinizing

squamous cell ca;
+LVSI;

High Risk			
Serotype 16	Detected	Serotype 31	Not detected
Serotype 18	Not detected	Serotype 45	Not detected
Intermediate Risk			
Serotype 33	Not detected	Serotype 56	Not detected
Serotype 35	Not detected	Serotype 58	Not detected
Serotype 39	Not detected	Serotype 59	Not detected
Serotype 51	Not detected	Serotype 66	Not detected
Serotype 52	Not detected	Serotype 68	Not detected
Low Risk			
Serotype 6	Not detected	Serotype 11	Not detected

Urine (catheter specimen) 1 April 2016

No malignancy

Gynecologic Cancer InterGroup Cervix Cancer Research Network



CT scan pelvis 31 Mar 2016:

Large mass involving the cervix – 7x5.5x5.5cm

Lesion abutts the bladder and rectum but no obvious infiltration;
Bladder outline smooth and regular; No free fluid in the abdomen.

No adnexal cystic or solid mass lesions are evident.

No significant inguinal or iliac LNs are identified.

Referred to a Gynae Oncologist

Gynecologic Cancer InterGroup Cervix Cancer Research Network



Gynae Oncologist:

LMP: 1/12 ago, regular menses but intermenstrual bleeding

Currently not sexually active and no partner;

Last PAP was done when the patient was pregnant

O/E: Left s/c LNs – 3cm in size

Breasts: NAD Abd: SNT; No HSM

PV: 6-7cm cervix mass with upper 1/3 vaginal involvement;
No VVF/RVF

PR: Para bilat, left to PSW

Plan FNA L s/c LN and full staging CT scan

FNA LN 8 Apr 2016: Metastatic squamous cell carcinoma

Gynecologic Cancer InterGroup Cervix Cancer Research Network



CT scan neck, chest, abd, pelvis 8 Apr 2016

Conglomerate of left cervical LNs

Cluster of superior mediastinal & middle mediastinal LNs

No pulmonary nodules

Large fungating cervix mass

Lesion inseparable from the posterior wall of the bladder. Rectum not invaded.

Multiple enlarged inguinal, iliac and para-aortic LNs

No liver lesions

Spleen, pancreas, adrenal glands, kidneys enhance normally;

No destructive bone lesions

Assessment: Cervix ca Stage IVB – referred for systemic Rx

Cervix Cancer Education Symposium, January 2019, South Africa

Gynecologic Cancer InterGroup Cervix Cancer Research Network



Medical Oncologist:

April 2016

1st line Cisplatin/Paclitaxel/Bevacizumab

<u>Target Lesion</u>	<u>08/04/2016</u>	<u>14/06/2016</u>	<u>26/08/2016</u>	<u>02/12/2016</u>	<u>30/03/2017</u>	<u>24/05/2017</u>
Left supraclavicular node (1)	26 x 33 mm	24 x 21mm	8 x 8mm	5 x 5 mm	5 x 5 mm	5 x 5mm
Left supraclavicular node (2)	23 x 20mm	16 x 14mm	8 x 10 mm	5 x 5mm	< 5 mm	< 5 mm
Left level 5 node	9 x 11 mm	5 x 4mm	7 x 7mm	6 x 5mm	6 x 5mm	6 x 4mm
Thoracic inlet node	25 x 12mm	9 x 6mm	5 mm	scar	scar	scar
AP window node	25 x 14mm	22 x 12mm	8 x 13 mm	7 x 10 mm	5 x 9 mm	5 x 7 mm
Left para-aortic node	16 x 15mm	10 x 8mm	5 x 5mm	4 x 5 mm	7 x 11 mm	10 x 19 mm
Left external iliac node	25 x 24mm	16 x 16 mm	8 x 11 mm	7 x 10 mm	7 x 8 mm	8 x 7mm
Right external iliac node	20 x 20 mm	18 x 17mm	17 x 16mm	15 x 16 mm	13 x 14 mm	12 x 26 mm
Cervix mass	72 x 70mm	38 x 47 mm	42 x 13mm	30 x 14mm	45 x 24mm	43 x 33mm
Sum of LDs	250 mm	167 mm	118 mm	87 mm	102 mm	119 mm

Cervix Cancer Education Symposium, January 2019, South Africa

Gynecologic Cancer InterGroup Cervix Cancer Research Network



May 2017

Gynae onc assessed patient – she still had significant local disease and was symptomatic – PVB;

Otherwise excellent general condition, ECOG 1

MDT discussion – RT for pelvic control

Gynecologic Cancer InterGroup Cervix Cancer Research Network



6 June 2017 started EBRT

7 June 2017 – patient's mother phoned, patient complaining of severe headaches; Pt took Stilpayne; Pt declined to be seen for an assessment; Counselling regarding admission if required and to consider MRI brain if indicated.

9 June 2017 – seen in consulting rooms for review, 4# EBRT

Headaches improved on NSAID; No N/V/D; Mild fatigue; Clinically well, CNS – no FND. Counselling at length.

Patient also asked about safety of sexual intercourse (she had started dating someone 3 months post dx and they were now engaged)

Gynecologic Cancer InterGroup Cervix Cancer Research Network



13 June 2017 – EBRT review – 6#

Pt well, no N/V, diarrhoea Grade 1; She noted a headache the day before settled on NSAID.

Clinically stable; no skin reaction.

21 June 2017 – EBRT review – 11#

Pt complaining of fatigue but also unable to sleep;

She noted mild PVB; Pt offered psych support but she felt she was coping and that she had enough support from her mother and fiancé.

Gynecologic Cancer InterGroup Cervix Cancer Research Network



23 June 2017 – patient came in again for review

Seen with fiancé

The patient said she could not cope anymore (mentally) and wanted to stop treatment. She felt extremely fatigued.

She was counselled at length. She decided to stop treatment (12#)

She said she would also make an appointment to see her medical oncologist again.

Gynecologic Cancer InterGroup Cervix Cancer Research Network



Medical Oncologist

Restarted Bevacizumab q21d until December 2017

CT scan Sep 2017

Stable disease; No hepatic, pulmonary or bone metastases.

US 15 January 2018

Right flank pain – new Rt hydronephrosis; Seen by urology – stented

CT 18 January 2018

Progressive disease – increase in the size of the cervix mass & LNs;
Subcutaneous oedema of the right upper leg related to circumferential infiltration of the right external iliac vessels.

Pulmonary metastases; No liver or bone metastases.

MRI brain January 2018

No brain metastases

Gynecologic Cancer InterGroup Cervix Cancer Research Network



Medical Oncologist

January 2018 2nd line systemic therapy

Cisplatin/Gemcitabine/Bevacizumab – 3 cycles completed

Admissions:

22 – 23 Feb

20 March – 6 April

11 – 27 April

8 – 11 May

13 May – 7 June

Cervix Cancer Education Symposium, January 2019, South Africa

Gynecologic Cancer InterGroup Cervix Cancer Research Network



US February 2018

DVT Right external iliac vein

US 20 March 2018

No hepatic metastases are noted. Large right pelvic sidewall mass with attenuation of the iliac vein and ureter. RP adenopathy.

There is relative narrowing of the third part of the duodenum which may be seen with an SMA syndrome (nutcracker sign).

CT 26 March 2018

Mixed response of the pulmonary nodules with the majority smaller while one nodule is significantly larger. Increased right-sided hydronephrosis; SMA syndrome

Gynecologic Cancer InterGroup Cervix Cancer Research Network



US 9 May 2018

Large mass infiltrating the right pelvic sidewall, right adnexa and bladder. Persistent right-sided hydronephrosis and hydroureter despite double-J stent.

Distended loop of small bowel in the pelvis possibly adherent to the mass in the right adnexa. If the patient has persistent nausea and vomiting consider malignant small bowel obstruction.

CT abd 10 May 2018:

Significant interval increase in size of the mass lesion in the pelvis which infiltrates the bladder & completely envelopes the right distal ureteric stent. Complete attenuation of the right external iliac vein with DVT in the right common femoral vein & marked subcutaneous edema of the right lower limb. Decreased right renal perfusion with increased right hydronephrosis, appropriately sited right ureteric stent. Features are in keeping with disease progression.

Gynecologic Cancer InterGroup Cervix Cancer Research Network



21 May 2018

Laparotomy for small bowel obstruction - ileostomy

CT chest 25 May 2018:

No pulmonary emboli; Progressive pulmonary metastases. New small left effusion with atelectatic changes in both lung bases.

Postoperative ileus with distended loops of small bowel but no transition zone.

Gynecologic Cancer InterGroup Cervix Cancer Research Network



CT abd 26 May 2018:

Distended loops of small bowel up to the ileostomy in keeping with ileus. Peritonitis with non encapsulated fluid throughout the entire abdomen. Locally advanced tumor in the right iliac fossae with retroperitoneal adenopathy. Liver metastases and pulmonary metastases.

Demised 6 June 2018

Gynecologic Cancer InterGroup Cervix Cancer Research Network



Summary 32 year old pt, single at dx; 2 year old;

Diagnosed **March 2016 with metastatic disease**; demised **June 2018**

?Some unnecessary S/I requested upfront; Initial CT missed pelvic LNs

Systemic therapy – chemotherapy and targeted therapy

RT for local control – defaulted treatment;

2018: PD with hydronephrosis, DVT, bowel obstruction, lung, liver mets

Other aspects of disease – psychosocial, sexual